Orlistat (marketed as Alli and Xenical): Early Communication about an Ongoing Safety Review
Audience: Endocrinological healthcare professionals, patients
FDA notified healthcare professionals and patients that it is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat. Orlistat…
No related posts.




facebook
rss
twitter